NURS 5338 FINAL EXAM ADVANCED PHARMACOLOGY FOR APRNS 200
QUESTIONS WITH VERIFIED ANSWERS & DETAILED RATIONALES
UNIVERSITY OF TEXAS AT ARLINGTON (UTA) – CP2 FINAL EXAM
LATEST 2026/2027 UPDATE |
GRADED A+
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–20)
1. A patient is prescribed a medication that is a weak acid with a pKa of
4.5. In which part of the body will this medication be most highly
absorbed?
A) The stomach (pH 1.5–3.5)
B) The small intestine (pH 5.5–7.0)
C) The large intestine (pH 7.0–8.0)
D) The rectum (pH 6.0–7.0)
Answer: A) The stomach (pH 1.5–3.5)
Rationale: Weak acids are non-ionized (and therefore lipid-soluble
and absorbable) in acidic environments. The stomach has a low pH
(1.5–3.5), which is below the pKa of the weak acid (4.5). According
to the Henderson-Hasselbalch equation, when the pH is lower than the
pKa, the weak acid is predominantly non-ionized, allowing for passive
diffusion across the gastric mucosa. Weak bases are better absorbed
in the alkaline environment of the small intestine.
2. A patient is taking a medication that undergoes extensive first-pass
metabolism. The prescriber decides to change the route of
administration to avoid this effect. Which route would be most
appropriate?
A) Oral
B) Sublingual
1
, C) Rectal
D) Enteral
Answer: B) Sublingual
Rationale: First-pass metabolism occurs when a drug is absorbed from
the gastrointestinal tract and passes through the portal circulation
to the liver, where it is extensively metabolized before reaching
systemic circulation. Sublingual administration bypasses the
gastrointestinal tract and portal circulation, allowing the drug to
be absorbed directly into the systemic circulation through the
highly vascularized sublingual mucosa. This avoids first-pass
metabolism and results in higher bioavailability.
3. A patient with hepatic impairment is prescribed a medication that is
highly protein-bound (98%). The nurse practitioner should be
concerned about which potential consequence?
A) Increased drug clearance
B) Decreased drug half-life
C) Increased free drug concentration and toxicity
D) Decreased drug absorption
Answer: C) Increased free drug concentration and toxicity
Rationale: In hepatic impairment, the liver produces less albumin,
leading to decreased protein binding. For a highly protein-bound drug
(98% bound), even a small decrease in protein binding can result in a
significant increase in the free (unbound) drug concentration. Only
the free drug is pharmacologically active and can exert therapeutic
and toxic effects. This can lead to drug toxicity even at standard
doses. The nurse practitioner should consider reducing the dose or
monitoring for signs of toxicity.
2
,4. A medication has a half-life of 4 hours. How many hours will it take
for the drug to reach steady state?
A) 8 hours
B) 12 hours
C) 16 hours
D) 20 hours
Answer: D) 20 hours
Rationale: Steady state is reached after approximately 4–5 half-lives
of the drug. With a half-life of 4 hours, steady state would be
reached in approximately 16–20 hours (4 half-lives = 16 hours, 5
half-lives = 20 hours). At steady state, the rate of drug
administration equals the rate of drug elimination, and plasma drug
concentrations remain relatively constant with each dose. This
principle is important for understanding dosing intervals and
loading doses.
5. A patient is prescribed a medication that is a CYP3A4 inducer. The
nurse practitioner should anticipate which effect on co-administered
medications metabolized by CYP3A4?
A) Increased serum concentrations of the co-administered medications
B) Decreased serum concentrations of the co-administered medications
C) No change in serum concentrations of the co-administered medications
D) Increased risk of toxicity from the co-administered medications
Answer: B) Decreased serum concentrations of the co-administered
medications
Rationale: CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine,
3
, St. John's wort) increase the activity of the CYP3A4 enzyme system,
leading to increased metabolism of medications that are substrates
for CYP3A4. This results in decreased serum concentrations of the
co-administered medications, potentially leading to therapeutic
failure. The nurse practitioner should monitor the patient for
decreased efficacy and consider dose adjustments. Conversely, CYP3A4
inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice)
decrease metabolism and increase serum concentrations.
6. A patient with renal impairment is prescribed a medication that is
primarily eliminated by the kidneys. The nurse practitioner should
anticipate which adjustment?
A) Increase the dose
B) Decrease the dose or increase the dosing interval
C) No change in dosing
D) Change to a different route of administration
Answer: B) Decrease the dose or increase the dosing interval
Rationale: In renal impairment, the kidneys are less able to
eliminate medications, leading to accumulation of the drug and its
metabolites. For medications primarily eliminated by the kidneys,
the dose should be reduced or the dosing interval should be
increased to prevent toxicity. The nurse practitioner should consult
renal dosing guidelines and monitor the patient's renal function
(creatinine clearance, estimated glomerular filtration rate) and
drug levels (if available). Some medications require dose adjustment
based on creatinine clearance.
7. The volume of distribution (Vd) of a medication is 100 L. This
indicates that the medication:
4
QUESTIONS WITH VERIFIED ANSWERS & DETAILED RATIONALES
UNIVERSITY OF TEXAS AT ARLINGTON (UTA) – CP2 FINAL EXAM
LATEST 2026/2027 UPDATE |
GRADED A+
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–20)
1. A patient is prescribed a medication that is a weak acid with a pKa of
4.5. In which part of the body will this medication be most highly
absorbed?
A) The stomach (pH 1.5–3.5)
B) The small intestine (pH 5.5–7.0)
C) The large intestine (pH 7.0–8.0)
D) The rectum (pH 6.0–7.0)
Answer: A) The stomach (pH 1.5–3.5)
Rationale: Weak acids are non-ionized (and therefore lipid-soluble
and absorbable) in acidic environments. The stomach has a low pH
(1.5–3.5), which is below the pKa of the weak acid (4.5). According
to the Henderson-Hasselbalch equation, when the pH is lower than the
pKa, the weak acid is predominantly non-ionized, allowing for passive
diffusion across the gastric mucosa. Weak bases are better absorbed
in the alkaline environment of the small intestine.
2. A patient is taking a medication that undergoes extensive first-pass
metabolism. The prescriber decides to change the route of
administration to avoid this effect. Which route would be most
appropriate?
A) Oral
B) Sublingual
1
, C) Rectal
D) Enteral
Answer: B) Sublingual
Rationale: First-pass metabolism occurs when a drug is absorbed from
the gastrointestinal tract and passes through the portal circulation
to the liver, where it is extensively metabolized before reaching
systemic circulation. Sublingual administration bypasses the
gastrointestinal tract and portal circulation, allowing the drug to
be absorbed directly into the systemic circulation through the
highly vascularized sublingual mucosa. This avoids first-pass
metabolism and results in higher bioavailability.
3. A patient with hepatic impairment is prescribed a medication that is
highly protein-bound (98%). The nurse practitioner should be
concerned about which potential consequence?
A) Increased drug clearance
B) Decreased drug half-life
C) Increased free drug concentration and toxicity
D) Decreased drug absorption
Answer: C) Increased free drug concentration and toxicity
Rationale: In hepatic impairment, the liver produces less albumin,
leading to decreased protein binding. For a highly protein-bound drug
(98% bound), even a small decrease in protein binding can result in a
significant increase in the free (unbound) drug concentration. Only
the free drug is pharmacologically active and can exert therapeutic
and toxic effects. This can lead to drug toxicity even at standard
doses. The nurse practitioner should consider reducing the dose or
monitoring for signs of toxicity.
2
,4. A medication has a half-life of 4 hours. How many hours will it take
for the drug to reach steady state?
A) 8 hours
B) 12 hours
C) 16 hours
D) 20 hours
Answer: D) 20 hours
Rationale: Steady state is reached after approximately 4–5 half-lives
of the drug. With a half-life of 4 hours, steady state would be
reached in approximately 16–20 hours (4 half-lives = 16 hours, 5
half-lives = 20 hours). At steady state, the rate of drug
administration equals the rate of drug elimination, and plasma drug
concentrations remain relatively constant with each dose. This
principle is important for understanding dosing intervals and
loading doses.
5. A patient is prescribed a medication that is a CYP3A4 inducer. The
nurse practitioner should anticipate which effect on co-administered
medications metabolized by CYP3A4?
A) Increased serum concentrations of the co-administered medications
B) Decreased serum concentrations of the co-administered medications
C) No change in serum concentrations of the co-administered medications
D) Increased risk of toxicity from the co-administered medications
Answer: B) Decreased serum concentrations of the co-administered
medications
Rationale: CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine,
3
, St. John's wort) increase the activity of the CYP3A4 enzyme system,
leading to increased metabolism of medications that are substrates
for CYP3A4. This results in decreased serum concentrations of the
co-administered medications, potentially leading to therapeutic
failure. The nurse practitioner should monitor the patient for
decreased efficacy and consider dose adjustments. Conversely, CYP3A4
inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice)
decrease metabolism and increase serum concentrations.
6. A patient with renal impairment is prescribed a medication that is
primarily eliminated by the kidneys. The nurse practitioner should
anticipate which adjustment?
A) Increase the dose
B) Decrease the dose or increase the dosing interval
C) No change in dosing
D) Change to a different route of administration
Answer: B) Decrease the dose or increase the dosing interval
Rationale: In renal impairment, the kidneys are less able to
eliminate medications, leading to accumulation of the drug and its
metabolites. For medications primarily eliminated by the kidneys,
the dose should be reduced or the dosing interval should be
increased to prevent toxicity. The nurse practitioner should consult
renal dosing guidelines and monitor the patient's renal function
(creatinine clearance, estimated glomerular filtration rate) and
drug levels (if available). Some medications require dose adjustment
based on creatinine clearance.
7. The volume of distribution (Vd) of a medication is 100 L. This
indicates that the medication:
4
